LOXO-435 is a selective small molecule inhibitor of FGFR3. It is active against both wild-type and oncogenically activated FGFR3, including FGFR3 fusion, point mutations, and expected acquired gated site resistance mutations.
For research use only. We do not sell to patients.
| Name | LOXO-435 |
|---|---|
| Iupac Chemical Name | (S)-4-(4-(3-chloro-4-(1-(5-fluoropyridin-2-yl)-2-hydroxyethoxy)pyrazolo[1,5-a]pyridin-6-yl)-5-methyl-1H-1,2,3-triazol-1-yl)piperidine-1-carbonitrile |
| Synonyms | LOXO-435 ; LOXO435 ; LOXO 435 |
| Molecular Formula | C23H22ClFN8O2 |
| Molecular Weight | 496.93 |
| Smile | CC1=C(N=NN1C2CCN(CC2)C#N)C3=CN4N=CC(Cl)=C4C(O[C@@H](C5=NC=C(C=C5)F)CO)=C3 |
| InChiKey | OYUCEQFRNJABJW-OAQYLSRUSA-N |
| InChi | InChI=1S/C23H22ClFN8O2/c1-14-22(29-30-33(14)17-4-6-31(13-26)7-5-17)15-8-20(23-18(24)10-28-32(23)11-15)35-21(12-34)19-3-2-16(25)9-27-19/h2-3,8-11,17,21,34H,4-7,12H2,1H3/t21-/m1/s1 |
| CAS Number | 2833703-74-3 |
| Related CAS | 2833703-74-3 |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | ≧98.0% |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO (DMSO : ≥ 100 mg/mL) |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |